NCT02860780View on ClinicalTrials.gov

A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

August 10, 2016

Primary Completion Date

May 15, 2017

Study Completion Date

May 15, 2017

Conditions
Advanced CancerMetastatic CancerColorectal CancerNon-small Cell Lung Cancer
Interventions
DRUG

prexasertib

Administered IV

DRUG

ralimetinib

Administered orally

Trial Locations (3)

28204

Carolinas Medical Center, Charlotte

37203

Sarah Cannon Research Institute SCRI, Nashville

50937

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cologne

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT02860780 - A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer | Biotech Hunter | Biotech Hunter